The FTSE 100 began Friday’s session on a positive note, gaining 23 points, reaching 9,124, as investors paid attention to ...

Pfizer Inc. (NYSE: PFE) delivered a stronger-than-anticipated second-quarter performance, beating analyst estimates and ...

Pfizer Inc. (NYSE: PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...

Q2 2025 Earnings Call Transcript August 6, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.83836, ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Trump Media shares dipped after launching its AI-powered Truth Search beta with Perplexity, even as the company reported $3.1 ...

While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...

Pfizer Inc displayed a robust performance in its Q2 2025 earnings call, with significant strides in revenue and research ...

Central to Nxera’s pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from ...

Live Updates Live Coverage Has Ended Tuesday Wrap-up 4:27 pm The Vanguard S&P 500 ETF closed at 577.35 Tuesday, down 0.5%.

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...